Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 158

1.

Biologic study of the effects of octreotide-LAR on growth hormone in unresectable and metastatic hepatocellular carcinoma.

Attia S, Holen KD, Thomas JP, Richie K, Dzelak T, Teeter K, Warren D, Bilger A, Fine J, Eickhoff J, Drinkwater N, Mulkerin D, Morgan-Meadows S.

Clin Adv Hematol Oncol. 2008 Jan;6(1):44-54.

PMID:
18322441
2.

Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue?

Jallad RS, Musolino NR, Kodaira S, Cescato VA, Bronstein MD.

Clin Endocrinol (Oxf). 2007 Aug;67(2):310-5.

PMID:
17555503
3.

Sandostatin LAR in acromegaly: a 6-week injection interval suppresses GH secretion as effectively as a 4-week interval.

Biermasz NR, van den Oever NC, Frölich M, Arias AM, Smit JW, Romijn JA, Roelfsema F.

Clin Endocrinol (Oxf). 2003 Mar;58(3):288-95.

PMID:
12608933
4.

Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.

Jallad RS, Musolino NR, Salgado LR, Bronstein MD.

Clin Endocrinol (Oxf). 2005 Aug;63(2):168-75.

PMID:
16060910
5.

A randomized trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast carcinoma.

Ingle JN, Suman VJ, Kardinal CG, Krook JE, Mailliard JA, Veeder MH, Loprinzi CL, Dalton RJ, Hartmann LC, Conover CA, Pollak MN.

Cancer. 1999 Mar 15;85(6):1284-92.

PMID:
10189133
6.

Effect of the somatostatin analog octreotide acetate on circulating insulin-like growth factor-1 and related peptides in patients with non-metastatic castration-resistant prostate cancer: results of a phase II study.

Friedlander TW, Weinberg VK, Small EJ, Sharib J, Harzstark AL, Lin AM, Fong L, Ryan CJ.

Urol Oncol. 2012 Jul-Aug;30(4):408-14. doi: 10.1016/j.urolonc.2010.06.014.

PMID:
20884247
7.

[Clinical outcome of a cohort of 63 patients with hepatocellular carcinoma treated with octreotide].

Rabe C, Pilz T, Allgaier HP, Halm U, Strasser C, Wettstein M, Sauerbruch T, Caselmann WH.

Z Gastroenterol. 2002 Jun;40(6):395-400.

PMID:
12055662
8.

Impact of biomarkers on disease survival and progression in patients treated with octreotide for advanced hepatocellular carcinoma.

Treiber G, Wex T, Röcken C, Fostitsch P, Malfertheiner P.

J Cancer Res Clin Oncol. 2006 Nov;132(11):699-708.

PMID:
16835748
9.

First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial.

Colao A, Pivonello R, Rosato F, Tita P, De Menis E, Barreca A, Ferrara R, Mainini F, Arosio M, Lombardi G.

Clin Endocrinol (Oxf). 2006 Mar;64(3):342-51.

PMID:
16487447
10.

A randomized, multicenter prospective trial assessing long-acting release octreotide pamoate plus tamoxifen as a first line therapy for advanced breast carcinoma.

Bajetta E, Procopio G, Ferrari L, Martinetti A, Zilembo N, Catena L, Alú M, Della TS, Alberti D, Buzzoni R.

Cancer. 2002 Jan 15;94(2):299-304.

11.

A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma.

Yuen MF, Poon RT, Lai CL, Fan ST, Lo CM, Wong KW, Wong WM, Wong BC.

Hepatology. 2002 Sep;36(3):687-91. Erratum in: Hepatology. 2003 Feb;37(2):489.

PMID:
12198662
12.

Impact of serum insulin-like growth factor-1 on early prognosis in acute myocardial infarction.

Yamaguchi H, Komamura K, Choraku M, Hirono A, Takamori N, Tamura K, Akaike M, Azuma H.

Intern Med. 2008;47(9):819-25.

13.
14.

Thymostimulin in advanced hepatocellular carcinoma: a phase II trial.

Dollinger MM, Behrens CM, Lesske J, Behl S, Behrmann C, Fleig WE.

BMC Cancer. 2008 Mar 13;8:72. doi: 10.1186/1471-2407-8-72.

15.

Clinical experience with Sandostatin LAR in patients with acromegaly.

Heijckmann CA, Menheere PP, Sels JP, Beuls EA, Wolffenbuttel BH.

Neth J Med. 2001 Dec;59(6):286-91.

PMID:
11744180
16.

[Experience in treating acromegalic patients with long-acting octreotide].

Szücs N, Mészáros J, Czirják S, Mondok A, Varga I, Gláz E.

Orv Hetil. 2002 May 12;143(19 Suppl):1066-70. Hungarian.

PMID:
12063862
17.

Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study.

Kouroumalis E, Skordilis P, Thermos K, Vasilaki A, Moschandrea J, Manousos ON.

Gut. 1998 Mar;42(3):442-7.

18.

Vascular endothelial growth factor monitoring in advanced hepatocellular carcinoma patients treated with radiofrequency ablation plus octreotide: a single center experience.

Montella L, Addeo R, Caraglia M, Faiola V, Guarrasi R, Vincenzi B, Palmeri A, Capasso E, Nocera V, Tarantino L, Ariete M, Martorelli A, Del Prete S.

Oncol Rep. 2008 Aug;20(2):385-90.

PMID:
18636202
19.

Treatment of metastatic osteosarcoma with the somatostatin analog OncoLar: significant reduction of insulin-like growth factor-1 serum levels.

Mansky PJ, Liewehr DJ, Steinberg SM, Chrousos GP, Avila NA, Long L, Bernstein D, Mackall CL, Hawkins DS, Helman LJ.

J Pediatr Hematol Oncol. 2002 Aug-Sep;24(6):440-6.

PMID:
12218590
20.

Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study.

Prete SD, Montella L, Caraglia M, Maiorino L, Cennamo G, Montesarchio V, Piai G, Febbraro A, Tarantino L, Capasso E, Palmieri G, Guarrasi R, Bianco M, Mamone R, Savastano C, Pisano A, Vincenzi B, Sabia A, D'Agostino A, Faiola V, Addeo R.

Cancer Chemother Pharmacol. 2010 Oct;66(5):837-44. doi: 10.1007/s00280-009-1226-z.

PMID:
20041325
Items per page

Supplemental Content

Support Center